Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : BIOTECH & TECHNOLOGY INVESTING *UNDERVALUED*{T/A F/A & V} -- Ignore unavailable to you. Want to Upgrade?

To: yosi s who wrote (19)	1/16/1999 3:28:00 PM
From: BRAVEHEART	Read Replies (1) \| Respond to of 423

Yes yosi, A ten year treatment history in Europe. I assume you are familiar with MERZ and Memantine given your statement. That you are familiar with their ongoing massive P-3 trials ( 3 actually ) both here and in Europe for Alzhimers related dementia. Suggesting efficacy in P-1 and P-2 both here and in Europe. The intrum P-3 data has been equally encouraging. This does suggest that NTI will have success with their P-2 trial in the very least. Certainly it does not remove all risk it just lowers it a notch. I would assume if Memantine has ( and it has ) been approved and on the market in Europe for 10 years to treat certain forms of dementia there is reason to believe that a reasonable amount of efficacy has been achieved. Who said anything about cureing dementia that is certainly not the endpoint? BEST WISHES LONE WOLF